Heron Therapeutics (HRTX) Gross Margin (2017 - 2026)

Heron Therapeutics has reported Gross Margin for 10 years, with the latest figure at 69.35% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 891.0% year-over-year to 69.35%; the trailing twelve-month figure through Mar 2026 stood at 71.12% (down 285.0% YoY), and the FY2025 full-year result was 73.31%, up 9.0% from the prior year.
• Gross Margin for Q1 2026 stood at 69.35%, down from 72.61% in the prior quarter.
• The five-year high for Gross Margin was 78.26% in Q1 2025, with the low at 36.53% in Q2 2023.
• Historically, Gross Margin has averaged 61.38% across 5 years, with a median of 69.35% in 2026.
• Annual changes were most pronounced in 2022 — Gross Margin soared 21018 bps — and 2026, when it slumped 891 bps.
• Heron Therapeutics' Gross Margin stood at 57.95% in 2022, then rose by 23 bps to 71.12% in 2023, then gained by 5 bps to 74.92% in 2024, then dropped by 3 bps to 72.61% in 2025, then fell by 4 bps to 69.35% in 2026.
• The last three Gross Margin figures came in at 69.35% (Q1 2026), 72.61% (Q4 2025), and 68.82% (Q3 2025), per Business Quant data.